Bicyclic imidazole-4-one derivatives: a new class of antagonists for the orphan G protein-coupled receptors GPR18 and GPR55

GPR18 and GPR55 are orphan G protein-coupled receptors (GPCRs) that interact with certain cannabinoid (CB) receptor ligands. In the present study bicyclic imidazole-4-one derivatives were discovered as new scaffolds for the development of antagonists for GPR18 and GPR55. Interaction with CB1 and CB2 receptors was also studied to assess selectivity. The presented extensive structure–activity relationship study of 49 derivatives investigated at all four GPCRs revealed structural requirements for the development of potent and selective GPR18 and GPR55 antagonists. (Z)-(2,3-Difluorobenzylidene)-6,7-dihydro-2H-imidazo[2,1b][1,3]thiazin-3(5H)-one (18) was identified as a selective GPR55 antagonist (IC50 3.15 μM). The most potent GPR18 antagonist was (Z)-2-(3-(4-chlorobenzyloxy)benzylidene)-6,7-dihydro-2H-imidazo[2,1b][1,3]-thiazin-3(5H)-one (32, IC50 0.279 μM, >36-fold selective vs. CB1 and GPR55, 14-fold selective vs. CB2) representing the first selective GPR18 antagonist. The new compounds may serve as lead structures and as tools to explore the (patho-)physiological roles of these orphan GPCRs and their potential as drug targets.

[1]  C. Müller,et al.  6-Bromo-8-(4-[(3)H]methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic Acid: a powerful tool for studying orphan G protein-coupled receptor GPR35. , 2013, Journal of medicinal chemistry.

[2]  A. Schiedel,et al.  8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35. , 2013, Journal of medicinal chemistry.

[3]  C. Müller,et al.  Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold. , 2013, Journal of medicinal chemistry.

[4]  M. Abood,et al.  GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors. , 2013, Life sciences.

[5]  S. Rees,et al.  Screening β-Arrestin Recruitment for the Identification of Natural Ligands for Orphan G-Protein–Coupled Receptors , 2013, Journal of biomolecular screening.

[6]  T. Karcz,et al.  Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55. , 2013, ACS medicinal chemistry letters.

[7]  V. B. Lu,et al.  N-Arachidonyl Glycine Does Not Activate G Protein–Coupled Receptor 18 Signaling via Canonical Pathways , 2013, Molecular Pharmacology.

[8]  M. Caron,et al.  Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. , 2011, Biochemistry.

[9]  D. McHugh,et al.  GPR18 in microglia: implications for the CNS and endocannabinoid system signalling , 2012, British journal of pharmacology.

[10]  T. Karcz,et al.  7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists. , 2012, Journal of medicinal chemistry.

[11]  J. Marcu,et al.  Cannabinoid receptors: nomenclature and pharmacological principles , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[12]  D. McHugh,et al.  Δ9‐Tetrahydrocannabinol and N‐arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC‐1B cells , 2012, British journal of pharmacology.

[13]  Stephen P. H. Alexander.  So what do we call GPR18 now? , 2012, British journal of pharmacology.

[14]  C. Henstridge.  Off-Target Cannabinoid Effects Mediated by GPR55 , 2012, Pharmacology.

[15]  A. Irving,et al.  Modulation of l-α-Lysophosphatidylinositol/GPR55 Mitogen-activated Protein Kinase (MAPK) Signaling by Cannabinoids* , 2011, The Journal of Biological Chemistry.

[16]  Luciano Milanesi,et al.  Homology modeling in tandem with 3D-QSAR analyses: a computational approach to depict the agonist binding site of the human CB2 receptor. , 2011, European journal of medicinal chemistry.

[17]  R. Ross.  L-α-lysophosphatidylinositol meets GPR55: a deadly relationship. , 2011, Trends in pharmacological sciences.

[18]  S. Dowell,et al.  Pharmacology of GPR55 in Yeast and Identification of GSK494581A as a Mixed-Activity Glycine Transporter Subtype 1 Inhibitor and GPR55 Agonist , 2011, Journal of Pharmacology and Experimental Therapeutics.

[19]  R. Leurs,et al.  Quantitative expression profiling of G‐protein‐coupled receptors (GPCRs) in metastatic melanoma: the constitutively active orphan GPCR GPR18 as novel drug target , 2011, Pigment cell & melanoma research.

[20]  R. Piñeiro,et al.  The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation , 2011, Oncogene.

[21]  Haitao You,et al.  Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands , 2011, Molecular pain.

[22]  Stephen P. H. Alexander,et al.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 , 2010, Pharmacological Reviews.

[23]  A. Irving,et al.  GPR55 ligands promote receptor coupling to multiple signalling pathways , 2010, British journal of pharmacology.

[24]  M. Abood,et al.  Pharmacological characterization of GPR55, a putative cannabinoid receptor. , 2010, Pharmacology & therapeutics.

[25]  Z. Vogel,et al.  N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor , 2010, BMC Neuroscience.

[26]  K. Mackie,et al.  The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo , 2009, Proceedings of the National Academy of Sciences.

[27]  Marc G Caron,et al.  Atypical Responsiveness of the Orphan Receptor GPR55 to Cannabinoid Ligands* , 2009, The Journal of Biological Chemistry.

[28]  H. Bradshaw,et al.  The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways , 2009, BMC Biochemistry.

[29]  J. Caldwell,et al.  Lipid G Protein-coupled Receptor Ligand Identification Using β-Arrestin PathHunter™ Assay , 2009, Journal of Biological Chemistry.

[30]  N. Stella,et al.  The therapeutic potential of novel cannabinoid receptors. , 2009, Pharmacology & therapeutics.

[31]  C. Müller,et al.  Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. , 2009, Bioorganic & medicinal chemistry.

[32]  A. Irving,et al.  The GPR55 ligand L‐α‐lysophosphatidylinositol promotes RhoA‐dependent Ca2+ signaling and NFAT activation , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  R. Pertwee.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids , 2005, The AAPS Journal.

[34]  S. Hjorth,et al.  The orphan receptor GPR55 is a novel cannabinoid receptor , 2007, British journal of pharmacology.

[35]  Atsushi Inoue,et al.  Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. , 2006, Biochemical and biophysical research communications.

[36]  P. Pacher,et al.  The Endocannabinoid System as an Emerging Target of Pharmacotherapy , 2006, Pharmacological Reviews.

[37]  Ken Mackie,et al.  Cannabinoid receptors as therapeutic targets. , 2006, Annual review of pharmacology and toxicology.

[38]  R. Pertwee,et al.  Evidence that the plant cannabinoid Δ9‐tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist , 2005, British journal of pharmacology.

[39]  C. Müller,et al.  Imidazo[2,1-b]thiazepines: synthesis, structure and evaluation of benzodiazepine receptor binding. , 2004, European journal of medicinal chemistry.

[40]  C. Müller,et al.  Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic acid prodrugs with peroral bioavailability. , 2004, Journal of medicinal chemistry.

[41]  J. Handzlik,et al.  Imidazo[2,1-b]thiazoles, imidazo[2,1-b]imidazoles and Pyrrolo[1,2-c]imidazoles. synthesis, structure and evaluation of benzodiazepine receptor binding , 2002 .

[42]  C. Müller,et al.  Imidazo-thiazine, -diazinone and -diazepinone derivatives. Synthesis, structure and benzodiazepine receptor binding. , 2001, European journal of medicinal chemistry.

[43]  D. Selley,et al.  Cannabinoid Receptor Agonist Efficacy for Stimulating [35S]GTPγS Binding to Rat Cerebellar Membranes Correlates with Agonist-induced Decreases in GDP Affinity* , 1998, The Journal of Biological Chemistry.

[44]  H. Yamamura,et al.  SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. , 1997, European journal of pharmacology.

[45]  K. Kieć‐Kononowicz,et al.  Benzylidene‐Substituted Imidazo‐Thiazole‐, Thiazine and ‐Thiazepine Derivatives: A New Class of Ligands for the Benzodiazepine Binding Site of GABAA Receptors. , 1997 .

[46]  K. Kieć‐Kononowicz,et al.  SYNTHESIS AND SPECTROSCOPIC PROPERTIES OF FUSED 5-ARYLIDENE-2-THIOHYDANTOIN DERIVATIVES , 1992 .

[47]  B. Fredholm,et al.  A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. , 1990, Analytical biochemistry.

[48]  K. Kieć‐Kononowicz,et al.  REACTION OF 5,5-DIPHENYL-2-THIOHYDANTOIN WITH 1,4-DIBROMOBUTANE. THE CRYSTAL AND MOLECULAR STRUCTURE OF 2,3,4,5-TETRAHYDRO-7,7-DIPHENYLIMIDAZO-[2,1-b]-THIAZEPINE-8(7H)-ONE , 1989 .

[49]  K. Kieć‐Kononowicz,et al.  Reaction of 5,5-diphenyl-2-thiohydantoin with ethyl-2,3-dibromopropionate. Crystal and molecular structure of ethyl-2-{2,3-dihydro-6,6-diphenylimidazo-[2,1-b]-thiazol-5(6H)-one} formate , 1987 .

[50]  K. Kieć‐Kononowicz,et al.  Reaction of 5,5-diphenyl-2-thiohydantoin with 1,2-dibromoethane.crystal and molecular structures of 2,3-dihydro-6,6-diphenylimi-dazo-[2,1-b]-thiazol-5(6h)-one and 2,3-dihydro-5,5-diphenylimi-dazo-[2,-1-b]-thiazol-6(5h)-one and their reactivity , 1985 .

[51]  M. Wieczorek,et al.  Reaction of 5,5-diphenyl-2-thiohydantoin with 1,3-dibromopropane under phase transfer catalytic conditions , 1981 .

[52]  M. Wieczorek,et al.  Reaction of 5,5-diphenyl-2-thiohydantoin with 1,3-dibromopropane , 1980 .

[53]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.